Company intelligence / Profile preview

Myris Therapeutics

Pittsburgh, Pennsylvania, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Emerging preclinical data show potential for improved efficacy and tolerability in oncology ADCs using proprietary ultra-high DAR (>50-300) technologies. Lead programs include oncology candidates (presented at AACR 2025) and legacy enzyme therapeutics advancing toward the clinic, with a Department of Defense-funded candidate for nerve agent protection approaching clinical nomination.[1][3][6][7]

Therapeutic areas: OncologyNeurologyRheumatology
Modalities: Antibody-drug conjugateBiologicPolymer-drug conjugate therapy
Industry: Biotech

Partnerships

U.S. Department of Defense (grants/contracts for enzyme therapeutics)

Beyond the preview

Go deeper on Myris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myris Therapeutics.

Explore the full profile